Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull, UK.
Department of Chemistry, University of Hull, Hull, UK.
Expert Opin Drug Discov. 2021 Apr;16(4):447-461. doi: 10.1080/17460441.2021.1832077. Epub 2020 Oct 28.
Diabetic kidney disease (DKD) is a leading cause of end-stage renal disease (ESRD), and 40% of patients with diabetes develop DKD. Although some pathophysiological mechanisms and drug targets of DKD have been described, the effectiveness or clinical usefulness of such treatment has not been well validated. Therefore, searching for new targets and potential therapeutic candidates has become an emerging research area.
The pathophysiological mechanisms, new drug targets and potential therapeutic compounds for DKD are addressed in this review.
Although preclinical and clinical evidence has shown some positive results for controlling DKD progression, treatment regimens have not been well developed to reduce the mortality in patients with DKD globally. Therefore, the discovery of new therapeutic targets and effective target-based drugs to achieve better and safe treatment are urgently required. Preclinical screening and clinical trials for such drugs are needed.
糖尿病肾病（DKD）是终末期肾病（ESRD）的主要原因，40%的糖尿病患者会发展为 DKD。虽然已经描述了 DKD 的一些病理生理机制和药物靶点，但这种治疗的有效性或临床实用性尚未得到很好的验证。因此，寻找新的靶点和潜在的治疗候选物已成为一个新兴的研究领域。
本文综述了 DKD 的病理生理机制、新药靶点和潜在的治疗化合物。
尽管临床前和临床证据表明某些控制 DKD 进展的方法取得了一些积极成果，但尚未制定出完善的治疗方案来降低全球 DKD 患者的死亡率。因此，迫切需要发现新的治疗靶点和有效的靶向药物，以实现更好和更安全的治疗。需要对这些药物进行临床前筛选和临床试验。
